pharmaphorum

DECEMBER 18, 2022

Science has taken a vertical growth trajectory, yet such innovations are, at best, slow to reach the patients in need. We believe that innovation in patient access models is the necessary catalyst to aid patients in starting on and staying on the therapies they need to improve their lives.

Biopharma 90

Biopharma Patients Prescription Medical 90

PM360

JUNE 11, 2022

Only 5% of patients ranked pharma companies as the most trusted player in the healthcare space, according to a 2021 survey of 500 patients from Accenture. But 71% also want publicly shared information about how patients’ perspectives were incorporated into the development of products and services. Noël Moossa.

Patients 59

Patients Pharma Education Media 59

Clarivate

APRIL 18, 2024

While the key players’ strategies differ, all are focused on bending the cost curve while increasing patient touchpoints and engagement. Strategy #1: innovate and create Amazon founder Jeff Bezos has said that overnight success takes about 10 years — and that ramp-up period may be what’s playing out for the ecommerce giant in healthcare.

Retail 52

Retail Healthcare Healthcare Physicians 52

PM360

JULY 21, 2022

Today’s physicians struggle to balance the increasing demands of patient loads, electronic health record (EHR) systems, and time spent on administrative tasks. 2 The percentage of healthcare providers willing to see pharmaceutical company reps in person had declined from 67% in 2018 to 54% in 2019.

Physicians 52

Physicians Media Pharma sales reps Electronics 52

MedCity News

JUNE 12, 2023

The goal was simple: provide access and focused support to patients remotely while simultaneously relieving overtaxed healthcare facilities. Combined, DTx and DCTs improve patient recruitment, retention, and access, allowing researchers to pull from underserved communities, including rural populations.

Food and Drug Administration 86

Food and Drug Administration Prescription Government FDA 86

Clarify Health

MAY 19, 2020

The time-consuming and resource-intensive path from the lab bench to the patient bedside starts with drug discovery, progresses to pre-clinical and clinical research, and then enters regulatory review. Any misstep in terms of pricing, reimbursement, or marketing could mean delays in providing therapies to the patients who need them most.

Biopharma 52

Biopharma Physicians Marketing Prescription 52

Clarivate

FEBRUARY 28, 2023

LHON mutation rate variability affects therapeutic efficacy Most LHON patients carry one of three pathogenic mitochondrial DNA mutations (11778G>A [ND4], 14484T>C [ND6] and 3460G>A [ND1]) known as primary LHON mutations. We identified patients with an LHON diagnosis using ICD-10 and ICD-9 codes H47.2 The Clarivate U.S.

Prescription 98

Prescription Patients Pharmacology Healthcare 98